SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The Revenue for the quarter ended  March 2022 of Rs. 40068.80 millions grew by 9.26 % from Rs. 36672.60 millions.The Net Loss for the quarter ended March 2022 is Rs. -12862.10 millions as compared to Net Profit of Rs. 1848.80 millions of corresponding quarter ended March 2021Operating profit surged to 13002.50 millions from the corresponding previous quarter of 7455.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 40068.80 36672.60 9.26 155859.80 141160.50 10.41 155859.80 141160.50 10.41
Other Income 4404.90 382.70 1051.01 11968.80 1920.70 523.15 11968.80 1920.70 523.15
PBIDT 13002.50 7455.00 74.41 38654.40 24490.80 57.83 38654.40 24490.80 57.83
Interest 911.90 1053.10 -13.41 3881.00 2675.20 45.07 3881.00 2675.20 45.07
PBDT -4459.00 5506.30 -180.98 16568.10 20920.00 -20.80 16568.10 20920.00 -20.80
Depreciation 3541.40 3220.70 9.96 13499.50 12364.30 9.18 13499.50 12364.30 9.18
PBT -8000.40 2285.60 -450.04 3068.60 8555.70 -64.13 3068.60 8555.70 -64.13
TAX 4861.70 436.80 1013.03 4068.50 131.70 2989.22 4068.50 131.70 2989.22
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -12862.10 1848.80 -795.70 -999.90 8424.00 -111.87 -999.90 8424.00 -111.87
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 32.45 20.33 59.63 24.80 17.35 42.95 24.80 17.35 42.95

Sun Pharma Inds. Share Price

1673.60 -1.60 (-0.10%)
20-Apr-2026 11:22 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.60
Dr. Reddys Lab 1237.20
Cipla 1235.85
Zydus Lifesciences 941.30
Lupin 2323.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×